Description:Bevacizumab is a monoclonal antibody used primarily in cancer therapy, specifically targeting vascular endothelial growth factor (VEGF). By inhibiting VEGF, it disrupts the formation of new blood vessels (angiogenesis) that tumors require for growth and metastasis. This drug is often employed in the treatment of various cancers, including colorectal, lung, and breast cancers. Bevacizumab is administered via intravenous infusion and is typically used in combination with other chemotherapy agents to enhance therapeutic efficacy. Its mechanism of action involves binding to VEGF, preventing it from interacting with its receptors on endothelial cells, thereby inhibiting tumor vascularization. Common side effects may include hypertension, increased risk of bleeding, and gastrointestinal perforations. As a biologic agent, Bevacizumab is produced through recombinant DNA technology, and its stability and efficacy are influenced by storage conditions and handling. The drug is classified under the category of anti-angiogenic agents and has been a significant advancement in targeted cancer therapies, contributing to improved patient outcomes in various malignancies.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
